Vous avez activé la version contrastée du site. Pour plus d'infos à ce sujet veuillez consulter cette page.

Publication du Pr Pierre-André Guerne

Partager Imprimer

Avenue de Beau-Séjour 26
1206 Genève
Suisse

Professeur Cem GABAY, Médecin-chef de service
Professeur
Cem Gabay
Médecin-chef de service

Articles originaux publiés ou acceptés dans des journaux à politique éditoriale

  1. Simonetta F, Guerne PA, Tirefort Y, Masouridi-Levrat S, Roosnek E, Chalandon Y. Complete and sustained remission of spondyloarthritis after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome. Joint Bone Spine. 2015; 82(3):216-7.
  2. Finckh A, Mc Carthy GM, Madigan A, Van Linthoudt D, Weber M, Neto D, Rappoport G, Blumhardt S, Kyburz D, Guerne PA. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: No significant effect in a randomized cross-over trial. Arthritis Res Ther, 15 October 2014.
  3. Wagner E, Arditi D, Guerne PA, Lanier C. Diagnostic imaging for atraumatic shoulder pain. Rev Med Suisse. 2013 25;9(399):1726-31.
  4. Guerne PA: Joint manifestations in connective tissue diseases. Rev Med Suisse. 2013 13;9(377):542, 544-6, 548.
  5. Lazarou IN, Guerne PA: Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol. 2013;40(5):550-64. Erratum in: J Rheumatol. 2013;40(7):1240.
  6. Siegrist CA, van Delden C, Bel M, Combescure C, Delhumeau C, Cavassini M, Clerc O, Meier S, Hadaya K, Soccal PM, Yerly S, Kaiser L, Hirschel B, Calmy A; H1N1 Study Group: Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine; Swiss HIV Cohort Study (SHCS). PLoS One. 2012;7(7).
  7. Cunningham G, Lädermann A, Guerne PA: Large paralabral cyst in the axilla. Joint Bone Spine. 2012; 79(6):627
  8. Siegrist CA, Ambrosioni J, Bel M, Combescure C, Hadaya K, Martin PY, Soccal PM, Berney T, Noble S, Meier S, Posfay-Barbe K, Grillet S, Kaiser L, van Delden C; H1N1 study group. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antivir Ther. 2012; 17(5):893-903.
  9. Hottinger AF, George AC, Bel M, Favet L, Combescure C, Meier S, Grillet S, Posfay-Barbe K, Kaiser L, Siegrist CA, Dietrich PY; H1N1 Study Group: A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients. Oncologist. 2012;17(3):436-45.
  10. Schäppi MG, Meier S, Bel M, Siegrist CA, Posfay-Barbe KM; H1N1 Study Group: Protective antibody responses to influenza A/H1N1/09 vaccination in children with celiac disease. J Pediatr Gastroenterol Nutr. 2012 Jun;54(6):817-9.
  11. Calmy A, Bel M, Nguyen A, Combescure C, Delhumeau C, Meier S, Yerly S, Kaiser L, Hirschel B, Siegrist CA; H1N1 Study Group: Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med. 2012 Apr;13(4):207-18.
  12. Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, Grillet S, Seebach JD, Kaiser L, Wunderli W, Guerne PA, Siegrist CA; Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011 Jun;63(6). IF 7.332
  13. Huys ACML, Guerne PA, Horvath J. Rheumatoid meningitis occurring during adalimumab and methotrexate treatment. Joint Bone Spine 2011. 2012 Jan;79(1):90-2.
  14. Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Bardin T: EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011; 70(4): 571-5. IF 8.111
  15. Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Pascual E: European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011; 70(4): 563-70. IF 8.111
  16. Vuilleumier N, Bas S, Pagano S,Montecucco F, Guerne PA, Finckh A, Lovis C, Mach F, Hochstrasser D, Roux-Lombard P, Gabay C: Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2010; 62(9): 2640-50. IF 7.332
  17. Jansen TL, Richette P, Perez-Ruiz F, Tausche AK, Guerne PA, Punzi L, Leeb B, Barskova V, Uhlig T, Pimentao J, Zimmermann-Gorska I, Pascual E, Bardin T, Doherty M: International position paper on febuxostat. Clin Rheumatol 2010. IF 1.668
  18. Bas S, Neff L, Viatte S, Neff L, Viatte S, Vuillet M, Spenato U, Guerne PA, Michel M, Tiercy JM, Butrimiene I, Gabay C: Relationship between gamma-interferon and interleukin-17 in Chlamydia trachomatis reactive arthritis. Clin Exp Rheumatol 2009; 27(5): 885-6. IF 2.396
  19. Genevay S, Finckh, A , F. Mezin, E. Tessitore, Guerne PA: Influence of Cytokines Inhibitors on Concentration and Activity of MMP-1 and MMP-3 in Disc Herniation. Arthritis Res Ther 2009, 11:R169 (11 November 2009). IF 4.271
  20. Butoescu N, Seemayer CA, Palmer G, Guerne PA, Gabay C, Doelker E, Jordan O: Magnetically retainable microparticles for drug delivery to the joint: efficacy studies in an antigen-induced arthritis model in mice. Arthritis Res Ther. 2009 May 19;11(3):R72. [Epub ahead of print]. IF 4.271
  21. Announ A, Palmer G, Guerne PA, Gabay C: Anakinra is a Possible Alternative in the Treatment and Prevention of Acute Attacks of Pseudogout in End-Stage Renal Failure. Joint Bone Spine 2009 Mar 14. [Epub ahead of print]. IF 2.250
  22. Bandelier C, Guerne PA, Genevay S, Finckh A, Gabay C: Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss Med Wkly. 2009 Jan 24;139(3-4):41-6. IF 1.681
  23. Genevay S, Finckh A, Payer M, Mezin F, Tessitore E, Gabay C, Guerne PA: Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc. Spine. 2008 Sep 1;33(19):2041-6. IF 2.624
  24. *Chollet-Janin A, Finckh A, Dudler J, Guerne PA: Methotrexate as an alternative therapy for chronic pyrophosphate arthropathy.  An exploratory analysis. Arthritis Rheum, 2007; 56: 688-92. IF 7.421
  25. Magne D, Mézin F, Palmer G, Guerne PA: The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1β and TNF-α. Inflamm Res, 2006; 55: 469-75. IF 1.210
  26. Bideau Mt, *Guerne PAt, Bianchi MP, Huber P : Benefits of patient instructors based teaching and assessment of musculoskeletal skills in medical students. Ann Rheum Dis, 2006; 65: 1626-30. IF 6.956
  27. Magne D, Palmer G, Barton JL, Mezin F, Guerne PA, Nicklin MJH, Gabay C: The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes. Arthritis Res Ther, 2006;8(3): R80. IF 2.965
  28. *Finckh A, Duryea J, Liang MH, Huang J, Daneel S, Forster A, Gabay C, Guerne P-A : The effectiveness of anti-TNF therapy in preventing progressive radiographic joint damage in Rheumatoid Arthritis. A population based study. Arthritis Rheum, 2006 Jan; 54: 54-9. IF 7.421
  29. Fineschi S, Reith W, Guerne PA, Dayer JM, Chizzolini C: Proteasome blockade exerts an anti-fibrotic activity by coordinately downregulating type I collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) and upregulating metalloproteinase-1 (MMP-1) production in human dermal fibroblasts. FASEB J, 2006; 20(3):562-4. IF 7.064
  30. Finckh A, Simard J, Gabay C, Guerne PA: Evidence for differential acquired drug resistance to anti-TNF agents in rheumatoid arthritis. Ann Rheum Dis, 2006; 65 (6): 746-52. IF 6.956
  31. Palmer G, Burger D, Mezin F, Magne D, Gabay C,Dayer J-M, Guerne P-A: The active metabolite of leflunomide, A77 1726, increases interleukin-1 receptor antagonist production in human synovial fibroblasts and articular chondrocytes. Arthritis Res Ther, 2004; 6(3):R181-9. IF 2.965
  32. Palmer G, Mezin F, Juge-Aubry CE, Platter-Zyberk C, Gabay C, Guerne P-A: Interferon-b stimulates interleukin-1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann Rheum Dis, 2004; 63: 43-9. IF 6.956
  33. Relic B, Bentires-Alj M, Ribbens C, Franchimont N, Guerne P-A, Benoît V, Merville M-P, Bours V, Malaise M: TNF-a Protects Human Primary Articular Chondrocytes from Nitric Oxide-Induced Apoptosis via NF-kB. Lab Invest, 2002; 82:1661-72. IF 3.859
  34. Guicheux J, Palmer G, Relic B, MezinF, Caverzasio J, Apostolides P, GauchatJ-F, GabayC, GuerneP-A: Primary human articular chondrocytes, dedifferentiated chondrocytes and synoviocytes exhibit differential responsiveness to interleukin-4: correlation with the expression pattern of the common receptor gamma chain. J Cell Physiol, 2002; 192: 93-101. IF 4.362
  35. Bas S, Perneger TV,Seitz M, Tiercy J-M, Roux-Lombard P, Guerne P-A: Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-filaggrin antibodies and IgM rheumatoid factors. Rheumatology, 2002; 41:809-815. IF 4.226
  36. *Genevay S, di Giovine FS, Pernegger T, Silvestri T, Stingelin S, Duff GW, Guerne P-A: Association of IL-4 and IL-1B gene variants with Larsen score progression in RA. Arthritis Rheum, 2002; 15;47:303-9. IF 7.421
  37. Palmer Gt, *Guerne P-At, Mezin F, Maret M, Guicheux J, Goldring M, Gabay C: Production of Interleukin-1 Receptor Antagonist by Human Articular Chondrocytes.  Arthr Res, 2002; 4:226-31. IF 2.965
  38. GenevayS, Saudan-KisterA, Guerne P-A: Intravenous gammaglobulins in refractory polymyositis: lower dose for maintenance therapy is effective. Ann Rheum Dis, 2001; 60.6: 635-6. IF 6.956
  39. *Relic B, Guicheux J, LubbertsE, Mezin F, Togninalli D, Garcia I, van den Berg W, Guerne P-A: Interleukin-4 and interleukin-13, but not interleukin-10, protect human synoviocytes from apoptosis. J Immunol, 2001; 15;166: 2275-2782. IF 6.387
  40. Uitz E, Fransen J, Langenegger T and Stucki G for the Members of the Swiss Clinical Quality Management in Rheumatoid Arthritis: Clinical Quality Management in rheumatoid arthritis: putting theory into practice. Rheumatology, 2000; 39:542-9. IF 4.226
  41. Fransen J, Langenegger T, Michel BA, Stucki G for the Members of the Swiss Clinical Quality Management in Rheumatoid Arthritis: Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology, 2000; 39:321-7. IF 4.226
  42. Bas S, Perneger TV,Mikhnevitch E, Seitz M, Tiercy J-M, Roux-Lombard P, Guerne P-A: Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis. Rheumatology, 2000; 39: 1082-88. IF 4.226
  43. Blouin J-L, Meeks M, Radhakrishna U, Sainsbury A, Gehrig C, Duriaux Saïl G, Bartoloni L, Dombi V, O'Rawe A, Walne A, Chung E, Afzelius BA, Armengot M, Jorissen M, Schidlow DV, Van Maldergem L, Walt H, Gardiner RM, Probst D, Guerne P-A, Delozier-Blanchet CD, Antonarakis SE: Primary Ciliary Dyskinesia: A Genome-Wide Linkage Analysis reveals extensive Locus Heterogeneity. Eur J Hum Genet, 2000; 8:109-118. IF 3.251
  44. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P: Contribution of Interleukin-17 to synovium matrix destruction in rheumatoid arthritis. Cytokine, 2000; 12: 1092-99. IF 2.012
  45. *Guerne PA,  Desgeorges A, Jaspar JM, Relic B, Peter R, Hoffmeyer P,Dayer JM: Effects of IL-6 and its soluble receptor on proteoglycan synthesis and NO release by human articular chondrocytes: comparison with IL-1. Modulation by dexamethasone. Matrix Biol, 1999; 18:253-260. IF 4.469
  46. *Silacci P, Dayer J-M, Desgeorges A, Peter R, Manueddu C, Guerne P-A: IL-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J Biol Chem, 1998; 273:13625-13629.
  47. Zanelli E, Huizinga T, Guerne P-A, Vischer TL, Tiercy J-M, Verduyn W, Schreuder GMT, Breedveld F, de Vries RRP: An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition. Immunogenetics 1998; 48: 394-401.
  48. Ibberson M, Péclat V, Guerne PA, Tiercy JM, Wordsworth P, Lanchburry J, Camilleri J, So AK: Analysis of T cell recpetor V alpha polymorphisms in rheumatoid arthritis. Ann Rheum Dis 1998; 57: 49-51.
  49. Guerne PA, Salvi M, Seitz M, Bruhlmann P, Rivier G, Frey D, Mermillod B, Vischer TL, Tiercy JM: Molecular analysis of HLA-DR polymorphism in polymyalgia rheumatica. Swiss Group for Research on HLA in Polymyalgia Rheumatica. J Rheumatol 1997; 24: 671-676.
  50. Sadallah S, Lach E, Lutz H, Schwarz H, Guerne P-A, Schifferli J: CR1, CD35 in synovial fluid from patients with inflammatory joint diseases. Arthritis Rheum 1997; 40:520-526.
  51. Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer TL, Guerne P-A: Concentrations and origins of soluble IL-6 receptor alpha (sIL-6Ra) in serum and synovial fluid. J Rheumatol, 1997; 24:1510-1516.
  52. Gabay C, Cekir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer TL, Yazici H, Guerne P-A: Levels of TNF soluble receptors are significantly higher in systemic lupus erythematosus than in other rheumatic diseases. Highly significant correlation with disease activity. J Rheumatol 1997; 14:303-308.
  53. Saudan-Kister A, Gabay C, Tiercy J-M, Mermillod B, Guerne P-A, Vischer TL: Adult seronegative arthritis with antinuclear antibodies: a distinct group of patients with a different immunogenetic pattern from seropositive rheumatoid arthritis and a good outcome. Rev Rhum 1996; 63: 313-320.
  54. Gabay C, Singwe M, Genin B, Meyer O, Mentha G, Le Coultre C, Vischer TL, Guerne P-A: Circulating levels of IL-11 and LIF do not significantly participate to the production of acute phase proteins by the liver. Clin Exp Immunol 1996; 105:260-265.
  55. Gabay C, Silacci P, Genin B, Mentha G, Le Coultre C, Guerne P-A: Soluble interleukin-6 receptor strongly increases the production of acute phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes. Eur J Immunol 1995; 25: 2378-2383.
  56. *Guerne P-A, Blanco F, Kaelin A, Desgeorges A, Lotz M: Growth factor responsiveness of human articular chondrocytes in aging and development. Arthritis Rheum 1995; 38:960-968.
  57. Gabay C, Genin B, Mentha G, Iynedjian P, Roux-Lombard P, Guerne P-A: Interleukin-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human hepatocyte primary cultures. Differential regulation in normal and tumoral hepatocytes. Clin Exp Immunol 1995; 100: 306-313.
  58. Gabay C, Gay-Crosier F, Roux-Lombard P, Meyer O, Maineti C, Guerne P-A, Vischer TL, Dayer J-M. Elevated serum levels of interleukin-1 receptor antagonist (IL-1Ra) in polymyositis-dermatomyositis: A biological marker of disease activity and a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994; 37: 1744-1751.
  59. Guerne P-A, Sublet A, Lotz M: Growth factor responsiveness of human articular chondrocytes. Distinct profiles in primary chondrocytes, dedifferentiated chondrocytes and fibroblasts. J Cell Physiol 1994; 158: 476-484.
  60. Roux-Lombard P, Punzi L, Hasler F, Bas S, Todesco S, Gallati H, Guerne P-A, Dayer J-M: Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485-489.
  61. Gabay C, Vischer T-L, Guerne P-A. Palindromic rheumatism. Appearance of chondrocalcinosis after 47 years of evolution. J Rheumatol 1993; 20:1610-1612.
  62. Gabay C, Roux-Lombard P, De Moerloose P,Dayer J-M, Vischer T-L, Guerne P-A. Absence of correlation between Interleukin-6 and C-reactive protein blood levels in systemic lupus erythematosus. A comparative study with rheumatoid arthritis. J Rheumatol 1993; 20: 815-821.
  63. Roux-Lombard, P and the Cytokine Consensus Study Group of The European Workshop for Rheumatology Research: Preliminary report on cytokine determination in human synovial fluids: a consensus study of the European Workshop for Rheumatology Research. Clin Exp Rheum 1992; 10: 515-520.
  64. *Guerne P-A, Weisman M: Palindromic rheumatism. Part or apart from the spectrum of rheumatoid arthritis. Am J Med 1992; 93: 451-460.
  65. Aellen P, Guerne P-A,Zenagui D, VischerT-L.L'arthropathie de l'hémochromatose:  manifestation souvent inaugurale de la maladie. Schweiz Med Wochenschr 1992; 122: 842-849.
  66. Guerne P-A, Lotz M: Interleukin-6 and transforming growth factor ß synergistically stimulate chondrosarcoma cell proliferation. J Cell Physiol 1991; 149: 117-124.
  67. *Lotz M, Guerne P-A: Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). J Biol Chem 1991; 266: 2017-2020.
  68. *Guerne P-A, Carson DA, Lotz M:  IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro.  J Immunol 1990; 144: 499-505.
  69. *Guerne P-A, Terkeltaub R, Zuraw B, Lotz M:  Inflammatory microcrystals stimulate interleukin 6 (IL-6) production and secretion from human monocytes and synoviocytes. Arthritis Rheum 1989; 32: 1443-1451.
  70. *Guerne P-A, Zuraw BL, Vaughan JH, Carson DA, Lotz M:  Synovium as a source of interleukin-6 in vivo. Contribution on local and systemic manifestations of arthritis.  J Clin Invest 1989; 83: 585-592.
  71. Guerne P-A, Piguet P-F, Vassalli P:  Production of interleukin 2, interleukin 3, and interferon by mouse T lymphocyte clones of Lyt-2+ and -2- phenotype. J Immunol 1984; 132: 1869-1871.
  72. Guerne P-A, Piguet PF, Vassalli P:  Positively selected Lyt-2+ and Lyt-2- mouse T lymphocytes are comparable, after Con A stimulation, in release of IL 2 and of lymphokines acting on B cells, macrophages, and mast cells, but differ in interferon production.  J Immunol 1983; 130: 2225-2230.
tLes 2 premiers auteurs ont contribué de manière équivalente au travail

Articles de revues publiés ou acceptés dans des journaux à politique éditoriale

  1. Guerne PA: Joint manifestations in connective tissue diseases. Rev Med Suisse. 2013 Mar 13;9(377):542, 544-6, 548.
  2. Lazarou IN, Guerne PA: Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol. 2013 May;40(5):550-64.
  3. Guerne PA: [Chondrocalcinosis and calcium pyrophosphate (CPP) crystal deposition disease]. Rev Med Suisse; 2010 6(240): 555-6, 558, 560-1. Review. French
  4. Guerne PA:  [Myositis: current data on the classification, diagnosis and treatment]. Rev Med Suisse. 2008 Mar 19;4(149):718, 720-2, 724 passim. Review. French
  5. Announ N, Guerne PA: Treating difficult crystal pyrophosphate dihydrate deposition disease. Curr Rheumatol Rep. 2008 Jul;10(3):228-34. Review
  6. Announ N, Guerne PA: [Polymyalgia rheumatica and giant cell arteritis: recent data and current situation]. Rev Med Suisse. 2008 Mar 19;4(149):696-8, 701. Review. French.
  7. Zaninetti-Schaerer A, Guerne PA : [Advances in the management of gout]. Rev Med Suisse, 2007 Mar 21;3(103):734-7.
  8. Announ N, Guerne, P- A : [Diagnosis and treatment of calcium pyrophosphate crystal-induced arthropathy.] Z Rheumatol, 2007 No, 66(7)573-8.
  9. Announ N, Guerne, P- A : [Calcium pyrophosphate dihydrate crystal induced arthropathy]. Rev Med Suisse, 2007 Mar 21;3(103):740-2.
  10. Guerne P-A, Stingelin-Guerne S: [Treatment of rheumatoid arthritis in 2005: prompt, agressive and customized]. Rev Méd Suisse, 2005, 1: 687-90
  11. Finckh A, Gabay C, Guerne P-A: Revue des effets protecteurs articulaires des inhibiteurs du TNF-a dans la polyarthrite rhumatoïde. Rev Méd de la Suisse Rom, 2004,124, 547-50
  12. Genevay S, Guerne P-A, Gabay C: Existe-t-il des arguments pour utiliser des inhibiteurs du TNF-a dans le traitement de la sciatique sévère? Rev Méd de la Suisse Rom, 2004,124 : 543-6.
  13. Guerne P-A: Cytokines and juvenile arthritis. Rev Rhum 1996; 63: 153-158. IF 0.774.

Éditoriaux publiés ou acceptés dans des journaux à politique éditoriale

/

Lettres publiées ou acceptées dans des journaux à politique éditoriale

  1. Bas S, Neff L,  Viatte S, Vuillet M, Spenato U, Guerne P-A, Michel M, Tiercy J-M, Butrimiene I, Gabay C: Relationship between gammainterferon and interleukin-17 in Chlamydia trachomatis reactive arthritis. Clin and Exp Rheumatol 2009: Sep-Oct;27(5):885-6.

 Articles originaux, de revues, lettres ou éditoriaux, soumis dans des journaux à politique éditoriale

/

Articles originaux, de revues, lettres ou éditoriaux, publiés ou acceptés dans des journaux sans politique éditoriale

  1. Guerne, P- A : Chondrocalcinose et arthropathies. La Gazette Médicale, 2015 No, 4(5) 18-21.Wolff H, Stalder H, Guerne PA: Stratégies en Médecine Ambulatoire. Monoarthrite aiguë. Primary Care 2005 (5) ; 5 : 98-103.IF 0.735.
  2. Wolff H, Guerne PA, Stalder H: Stratégies en Médecine Ambulatoire. Lombalgie aiguë. Primary Care 2005 (5) ; 3 : 52-56.IF 0.735.
  3. Guerne P-A, Vaughan JH, Carson DA, Terkeltaub B, Lotz M:  Interleukin-6 (IL-6) and joint tissues.  NY Acad Sci 557:558, 1989.
  4. P.-A. Guerne: Utilisation des anti-TNF dans les spondarthropathies séronégatives. Med et Hyg 2003; 61:562-9.
  5. Thurler F, Rivier G, Guerne P-A, Sauvain M-J, Saurenmann T, Bolz D, Hofer M: Arthrites chroniques de l'enfant: approche pratique et données épidémiologiques. Rev Méd de la Suisse Rom, 2002,122, 602-5.
  6. Gerster J.-C, P.-A. Guerne, J. Dudler, O. Lamy: Acquisitions thérapeutiques 2002: Rhumatologie. Med et Hyg 2003; 61:57-65.
  7. Hofer M, Rivier G, Guerne P-A, Girardin E: La dermatomyosite juvénile: une maladie différente de la forme adulte?. Med et Hyg 2001; 59: 898-903.
  8. Guerne P-A: Rôle de l’interleukine 1 dans l’arthrose. Rev du Prat, 1998, 48: S13-S15.
  9. Roux-Lombard P, Guerne P-A: Utilisation diagnostique des auto-anticorps dans les maladies immuno-inflammatoires. Med et Hyg 1998; 56: 405-414.
  10. Guerne P-A: Les mécanismes de l'inflammation microcristalline. Revue du Praticien 1994; 2:161-166.
  11. Guerne P-A: Rhumatisme palindromique et arthropathies intermittentes. Med et Hyg 1994; 52: 622-625.
  12. Guerne P-A: Utilisation diagnostique des auto-anticorps en rhumatologie. Med et Hyg 1992; 50: 824-873.
  13. Guerne P-A, Vischer TL: L'interleukine-6, parmi les autres cytokines, dans les rhumatismes. Med et Hyg 1991; 49: 869-873.
    1. Guerne P-A, Vaughan JH, Carson DA, Terkeltaub B, Lotz M:  Interleukin-6 (IL-6) and joint tissues.  NY Acad Sci 557:558, 1989.

Articles originaux, de revues, lettres ou éditoriaux, soumis dans des journaux sans politique éditoriale

/

Livres

/

Chapitres de livres

    1. Sordet C, Guerne P-A, Sibilia J. Les arthropathies microcristallines. Immunopathologie, pp 167-175. Edité par le Collège des Enseignants d’Immunologie des Université de Langue Française, Coordonné par MC Béné, JD Lelièvre, J Sibilia. Editions Elsevier Masson. 2015
    2. Guerne P-A andTerkeltaub R. CPPD Deposition Disease: Epidemiology, Clinical Features, Diagnosis, and Treatment. Gout & Crystal-Induced Arthropathies, edited by Dr. Robert Terkeltaub. Elsevier. Philadelphia. 2015
    3. P Hasler, A de Vere-Tyndall, Guerne P-A. Les spondylarthropathies. Livre de poche de Rhumatologie, pp 116-38. Edité par PM Villiger et M Seitz. Editions Médecine-Sciences Flammarion. Paris. 2008
    4. Guerne P-A. Goutte. Scientific Units Recommendations Formulas. Guide thérapeutique de Médecine Interne & Diagnostic différentiel selon INVESTI-MED©. Guidelines pour la Suisse, pp 844-7. Edité par Ph Furger et coll. Editions D & F GmbH. Suisse. 2006
    5. Guerne P-A. Chondrocalcinose et Rhumatismes à hydroxyapatite. Scientific Units Recommendations Formulas. Guide thérapeutique de Médecine Interne & Diagnostic différentiel selon INVESTI-MED©. Guidelines pour la Suisse, pp 848-9. Edité par Ph Furger et coll. Editions D & F GmbH. Suisse. 2006
    6. Guerne P-A. Ostéonécrose aseptique. Scientific Units Recommendations Formulas. Guide thérapeutique de Médecine Interne & Diagnostic différentiel selon INVESTI-MED©. Guidelines pour la Suisse, pp 858-9. Edité par Ph Furger et coll. Editions D & F GmbH. Suisse. 2006
    7. Miossec P, Guerne P-A. TGF-ß, Inflammation, pp 421-429. Edité par Peltier, Polla et Russo-Marie. John Libbey, Paris, France. 1998.
    8. Guerne P-A, Interleukine-6, Inflammation, pp 395-406. Edité par Peltier, Polla et Russo-Marie. John Libbey, Paris, France. 1998.
    9. Pasqualini C, Guerne P-A. Restellini A, Auckenthaler R. Arthrite aiguë, Urgences médicales. pp 330-8. Edited by Restellini, Malè and Unger. Médecine et Hygiène, Genève, Suisse.  1997.
    10. Guerne P-A. Adult Still disease, Therapy of systemic rheumatic disorders, pp 461-72. Edited by Van de Putte, Furst, van Riel and Williams. Marcel Dekker Inc, New York, USA. 1997.
    11. Guerne P-A. Palindromic Rheumatism and recurrent arthritis, Therapy of systemic rheumatic disorders, pp 425-59. Edited by Van de Putte, Furst, van Riel and Williams. Marcel Dekker Inc, New York, USA. 1997.

< RETOUR

Dernière mise à jour : 29/01/2019